Table 3 Summary of baseline CD30... | American Society of Hematology

Table 3

Summary of baseline CD30 expression in DLBCL by central review and computer-assisted methods and summary of baseline sCD30 for patients treated with single-agent brentuximab vedotin

	CR (n = 8)		CR + PR (n = 21)		Nonresponders (n = 27)
	No.	%	No.	%	No.	%
sCD30 expression at baseline, ng/mL*
Median	103		121		223
Range	44-485		44-1341		36-9429
% CD30⁺ malignant cells by visual central review
Median	11		25		25
Range	0-90		0-90		0-100
Patients with <10% CD30⁺ malignant cells by visual central review	4	50	8	21	7	26
% CD30⁺ in all cells by computer-assisted methods
Median	58.5		37.4		20.7†
Range	1-95		1-95		0-100

	CR (n = 8)		CR + PR (n = 21)		Nonresponders (n = 27)
	No.	%	No.	%	No.	%
sCD30 expression at baseline, ng/mL*
Median	103		121		223
Range	44-485		44-1341		36-9429
% CD30⁺ malignant cells by visual central review
Median	11		25		25
Range	0-90		0-90		0-100
Patients with <10% CD30⁺ malignant cells by visual central review	4	50	8	21	7	26
% CD30⁺ in all cells by computer-assisted methods
Median	58.5		37.4		20.7†
Range	1-95		1-95		0-100

Normal range, <29 ng/mL.

†

Patients with data available, n = 24; no data available, n = 3.

View Large

This Feature Is Available To Subscribers Only